Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905279 · ClinicalTrials.gov registry record · NA
Spider Phobia Opposite Action Treatment Study
A NA study, sponsored by University of Texas at Austin.
- Terminated
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT02905279: Clinical Trial NA study, sponsored by University of Texas at Austin.
NCT02905279 is a NA study that was terminated before completion, run by University of Texas at Austin. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02905279, a NA study, was terminated before completion, sponsored by University of Texas at Austin.
- TERMINATED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study tests the effectiveness of exposure therapy for fear of spiders as enhanced by the use of antagonistic or opposite actions during treatment. The goal of the study is to compare the efficacy threat-relevant opposite actions and threat-irrelevant opposite actions in extinguishing fear.
Primary Outcome
Change in peak subjective fear (0 - 100 scale), behavioral approach (0 - 13 scale), and physiological reactivity (heart rate and skin conductance) to a live spider not used during treatment (generalization context) from pre-treatment to follow-up
Interventions
- BEHAVIORAL Exposure Therapy
- BEHAVIORAL Biofeedback Relaxation Training
- BEHAVIORAL Exposure with Threat-Relevant Opposite Actions
- BEHAVIORAL Exposure with Threat-Irrelevant Opposite Actions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2017-12-12 |
| Phase | NA |
Why NCT02905279 stopped before completion
NCT02905279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Exposure Therapy is the first listed.
NCT02905279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02905279 about?
NCT02905279 is a clinical study titled "Spider Phobia Opposite Action Treatment Study". This study tests the effectiveness of exposure therapy for fear of spiders as enhanced by the use of antagonistic or opposite actions during treatment. The goal of the study is to compare the efficacy threat-relevant opposite actions and threat-irrelevant opposite actions in extinguishing fear.
What is the current status of trial NCT02905279?
This trial is currently terminated. It is a NA study. The enrollment target is 44 participants. The study started on 2016-06-01. Estimated completion is 2017-12-12.
What interventions are being tested in trial NCT02905279?
The interventions under investigation include: Exposure Therapy (BEHAVIORAL), Biofeedback Relaxation Training (BEHAVIORAL), Exposure with Threat-Relevant Opposite Actions (BEHAVIORAL), Exposure with Threat-Irrelevant Opposite Actions (BEHAVIORAL).
Who is sponsoring clinical trial NCT02905279?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02905279's enrollment target sits among peer trials
44 1423rd of 2000 higher than 566 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI